header logo image


Page 572«..1020..571572573574..580590..»

Freezing Life: The Current Trends in Cryopreservation – Technology Networks

May 1st, 2020 9:44 pm

Cryopreservation has become an indispensable step in the daily routine of scientific research as well as in a number of medical applications, ranging from assisted reproduction and transplantations to cell-based therapies and biomarker identification. It is hardly possible to picture todays scientific and medical advancements without this technique.The successful development and implementation of all the therapeutic and scientific discoveries involving cryopreservation relies on the correct and safe translation of the method from the laboratory to the clinical and manufacturing scale.

With the need to correctly use this technique, more research is focusing on optimizing cryopreservation methods and investigating what the long-term effects and consequences are on the physiology of the cryopreserved material.

An important part of cell therapy research is focused on adult stem cells (ASCs). ASCs can be derived from different sources such as peripheral blood, bone marrow or adipose tissue and display strong promises because of their capacity to differentiate into any cell type of the human body.In recent work3, the team of Michael Pepper at the Institute for Cellular and Molecular Medicine in Pretoria, South Africa, explored the effects of cryopreservation on the differentiation ability of adipose tissue-derived stem cells (ADSCs). After analyzing gene expression of key adipogenic genes and the degree of differentiating cells, characterized with high levels of CD36 and intracellular lipid droplets, the scientists reported that slow freeze cryopreservation of cells shortly after their isolation causes no alterations on their ability to differentiate. Pepper is convinced of the necessity to perform such analysis when cryopreserving important cell pools: It is critical to do a post-thaw analysis of cell function to determine how the cryopreservation may have affected the cells.His team is analyzing the effects of cryopreservation on other cell types largely used in cell-based therapies such as hematological stem cells and peripheral blood mononuclear cells (PBMCs). Although they didnt observe major alterations in terms of immunophenotyping or the post-thaw proliferation of the cells, Pepper expresses his concern that more subtle characteristics might be affected.

Correct cryopreservation of cells intended for therapeutic use is crucial. This is very important particularly as cells may persist for a long time in the recipient. This area of cell therapy research definitely requires more attention, Pepper says. Moreover, his words reflect on the need to evaluate not only the direct post-thaw recovery, but to look deeper into the late-onset effects cryopreservation might have and ensure that transplanted cells have preserved their therapeutic properties.

In contrast to slow freezing, vitrification relies on the fast freezing of the material by putting it in high concentration of cryoprotectant and in contact with liquid nitrogen. This method allows the direct transition of water from liquid to solid state without crystal formation. The highly concentrated cryoprotectant prevents ice formation and therefore there is no need for slow cooling.

Although vitrification has a great potential, there are a couple of parameters that are a point of concern. The quick and drastic freeze is possible thanks to the high concentration of cryoprotectant, but the latter is also associated with higher toxicity. In some cases, an additional limitation is the direct contact of the sample with liquid nitrogen which is a predisposition for viral or bacterial contamination.The team of Christiani Amorim at the Institute for Experimental and Clinical Research in Louvain, Belgium, is approaching the challenges of vitrification in the context of ovarian auto-transplantation. Ovarian auto-transplantation consists of preserving a piece of ovarian tissue with active follicles from the pre-therapeutic ovary of a cancer patient, as chemotherapy often has damaging effects on the reproductive organs. This tissue sample will be conserved and auto-transplanted onto the patients ovary when she has recovered and wishes to become pregnant.In their recent research4, the authors used stepped vitrification, in which the concentration of the cryoprotectant is gradually increased while simultaneously temperature decreases. This avoids ice crystal formation and also prevents cryoprotectant toxicity.Although stepped vitrification has previously given good results in bovine ovarian tissue5, this was not the case for human ovarian tissue. The scientists didnt detect normal follicles following thawing and linked this to high cryoprotectant toxicity. Indeed, they observed all signs of dimethyl sulfoxide (DMSO)-related cell membrane damage: significant organelle damage, cell membrane disintegration and apoptosis. These observations imply on the variability of outcomes that the method could give when applied to the same type of tissue but from a different organism.Amorim is positive about the future of their method and recognizes the need for further research on the topic: I can see a great potential in the stepped vitrification approach, but I also believe that there is a lot we still need to learn before thinking about using it as method of choice for human ovarian tissue cryopreservation. The high cryoprotectant concentration that should be applied in this approach is my first concern. () Our study clearly showed that 50% DMSO is too high, so we need to try lower concentrations or combine it with other cryoprotectants.

Read more:
Freezing Life: The Current Trends in Cryopreservation - Technology Networks

Read More...

Global Cord Blood Corporation Provides Further Update on COVID-19 – BioSpace

May 1st, 2020 9:44 pm

HONG KONG, April 27, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today provided an update on the impact of the 2019 novel coronavirus ("COVID-19") on the Company's expected fiscal 2021 operations.

Based on information available to date, management estimates that the Company's new subscriber number in fiscal 2021 will decrease to 60,000-65,000, a 19%-29% decrease from the Company's fiscal 2020 new subscriber target, which is 80,000-85,000.

Under the anti-pandemic policies and measures taken by the Chinese government, the risk levels associated with major cities has decreased, and social and economic activities are gradually resuming. However, hospitals, which are the Company's key promotion and marketing channel, remain at the forefront in fighting this pandemic and remain under strict supervision and control. In the Company's key markets of Beijing municipality, Guangdong province, and Zhejiang province, the Company's usual marketing and promotion activities are significantly impacted by the control measures implemented by authorities and hospitals, prompting it to constantly readjust its marketing and promotion activities.

During this difficult time, the Company has prioritized employee safety and protection by providing personal protective equipment ("PPE") to everyone, especially the frontline sales team, and by implementing additional disinfection measures and work streams in its day-to-day operating procedures. The management team has also recalibrated its marketing and promotion efforts in order to better serve and engage with target and existing clients. As a result, operating costs have increased.

The negative economic impact brought forth by the COVID-19 pandemic has affected numerous industries and further erodes already weak consumer sentiment. GCBC management expects that these conditions, compounded by other factors, will adversely affect and potentially delay potential clients' pregnancy plans. Therefore, management believes it is possible that the number of newborns in the Company's respective regions will remain low in the near term. While the world is facing various challenges in response to COVID-19, China may continue to tighten its anti-pandemic policies and measures, which would add further headwinds to the recovery pace of China's economy and consumer confidence. GCBC management does not expect these conditions to be significantly improved in the near term.

Under the impact of the COVID-19 pandemic, the Company management is not optimistic regarding the general operating environment. Current operating data points to the low end of the expected fiscal 2021 new subscriber range. The management would like to remind investors that the above estimation is a forecast that reflects the Company's current and preliminary views, which is subject to change and substantial uncertainties, particularly in view of the potential impact of the COVID-19 outbreak, the effects of which are difficult to analyze and predict. The management will continue to monitor the evolvement of the pandemic and does not exclude the possibility of further adjusting the Group strategy and target as future situation and events unfold. Meanwhile, the management will continue to proactively explore and identify opportunities within the healthcare industry value chain to ensure the Group future growth over the long run.

About Global Cord Blood Corporation

Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at: http://www.globalcordbloodcorp.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

For more information, please contact:

Global Cord Blood CorporationInvestor Relations DepartmentTel: (+852) 3605-8180Email: ir@globalcordbloodcorp.com

ICR, Inc.William ZimaTel: (+86) 10-6583-7511U.S. Tel: (646) 405-5185Email: William.zima@icrinc.com

View original content:http://www.prnewswire.com/news-releases/global-cord-blood-corporation-provides-further-update-on-covid-19-301047374.html

SOURCE Global Cord Blood Corporation

Company Codes: NYSE:CO

Read the original:
Global Cord Blood Corporation Provides Further Update on COVID-19 - BioSpace

Read More...

Stem Cell Restore Helps Regain Youthful Strength And Energy – ZOBUZ – Zobuz

May 1st, 2020 9:44 pm

Stem Cell Restore is a formula that works toward improving your health on a cellular level to decrease age-related weakness and fatigue. This product employs natural ingredients for reaching its goals such as resveratrol, black current cocktail, icariin, and grape seed.

Multiple research works from renowned universities back the approach that this product takes. The best part is that it makes you feel stronger, younger, more refreshed, and more energetic without requiring you to get injected with needles. A simple and convenient solution. Another anti-aging plus weight loss supplement that you can opt for is Resurge. This is a new formula by John Barban. Interested folks can learn more about Resurge customer reviews on USAToday.

Stem Cell Restore Review

Aging is the only thing in your life that is bound to happen. Unfortunately, it is not the best experience. Sure, it gives you wisdom, but those wrinkles, that weakness, declining energy levels all these negative factors completely loot the good things. After all, no one likes to wake up in the morning to feel down and weak. No one likes it when it their joints ache or when they look in the mirror to see a dull reflection.

This brings us to possible solutions that you can go for. One of these is Stem Cell Restore. This is a potent dietary supplement that has been made using natural ingredients. The product is backed by science which is what marks it as reliable. Since it comes in the form of capsules, it can be a convenient addition to your routine. Hence, if you are on the lookout for an age-reversing formula, this is one that you can invest in.

Why Choose This Product?

Around the globe, women and men alike are waiting for a magical solution for saving themselves from accelerated aging. There certainly are many options available out there. However, most of these are not worth it. Why? Because they come with negative side effects. Not to mention, these so-called techniques for erasing the effects of aging are all supremely painful. They involve countless injections or an elaborate surgery.

Would you like to still go for these youth preserving tactics? Surely, youre at the very least hesitant. If you decide to go ahead nevertheless, know that the procedures are expensive. They cost hundreds of dollars and still, they are unnatural and eventually make your skin sag. This is where Stem Cell Restore comes into the picture and steals the limelight. The dietary supplement is based on the concept of stem cell surgery.

However, it has three favorable points that win over any surgery. First of all, it doesnt cost as much. In fact, you get to become youthful, energetic, and strong all with a solution that is less than $100. Secondly, the product happens to be completely natural. It doesnt contain any harmful components such as chemicals, additives, preservatives, and the like. This translates to safe usage. Lastly, theres no needles involved; you are just supposed to take the pills regularly.

Working Of This Product

Stem Cell Restore taps into the idea of repairing cells and rejuvenating them. By doing so, it is able to refresh your health completely. All your parts from tendons and joints to your heart and kidneys are able to function better as a result. Old cells are repaired at a fast rate and new ones are created. This makes you feel fresher, and more active. Its not uncommon of people to experience bodily aches and fatigue after crossing 30 years of age.

This product is a suitable solution for everyone. It gets to the core of preserving youth and improves health. Moreover, it also tackles the issue of inflammation which is what disturbs health in numerous ways. Unlike mainstream products, your skin is not the only organ that benefits. In fact, your entire body experiences the effects. To reach its goals, the formula employs only natural ingredients which are effective at their job. As mentioned above, Resurge is another formula for deep sleep and anti-aging. It comes with a money-back guarantee. You can check out more Resurge reviews on Yahoo Finance before deciding which one to buy among the two.

Ingredients Of This Product

Stem Cell Restore has an entirely natural composition. It doesnt comprise of any such ingredients which can have damaging effects in the short- or long-run. The product is a winner mainly because of this. No additives, fillers or other such harmful components are present in the formula. Since all the ingredients are completely organic you dont have to worry about any negative side effects of use. Lets take a look at the ingredients:

Pricing Of The Product

Did you know that you can get this product for absolutely free? Yes, thats true. For a trial period, the dietary supplement is entirely free of cost. You just have to pay for shipping and handling which just requires $9.95 from your wallet. The trail period lasts for 30 days.

If the product satisfies you, its yours and automatically charges are deducted from your account or card. Thats simple and gives you a chance to see whether or not this supplement actually works. There are also three bonus products that tag along with this supplement. These come for free as well. Heres a list of the bonus product that accompany:

Verdict

Stem Cell Restore is a great product for maintaining youthful energy and strength. The product is great for recovering from the pain and fatigue that usually occurs after the age of 30. This formula repairs and encourages the production of cells through the body. In this way, it improves each organs functionality and hence, overall health. You can know more about this dietary supplement by visiting its website online.

Related

Go here to see the original:
Stem Cell Restore Helps Regain Youthful Strength And Energy - ZOBUZ - Zobuz

Read More...

Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy? – Yahoo Finance

May 1st, 2020 9:44 pm

The market expects Fate Therapeutics (FATE) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2020. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This clinical-stage biotech company that develops stem cell treatments is expected to post quarterly loss of $0.38 per share in its upcoming report, which represents a year-over-year change of -26.7%.

Revenues are expected to be $2.07 million, down 21.3% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 49.28% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Fate Therapeutics?

For Fate Therapeutics, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +13.16%.

Story continues

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination indicates that Fate Therapeutics will most likely beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Fate Therapeutics would post a loss of $0.39 per share when it actually produced a loss of $0.37, delivering a surprise of +5.13%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Fate Therapeutics appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportFate Therapeutics, Inc. (FATE) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

Visit link:
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Read More...

Coronavirus (COVID-19) Business Impact Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size of Dynamics, Products, Application Forecast…

May 1st, 2020 9:44 pm

Study on the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The report on the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market reveals that the Platelet Rich Plasma and Stem Cell Alopecia Treatment market is anticipated to grow at a CAGR of ~XX% during the forecast period (2019-2029). The report provides a thorough assessment of the impact of the COVID-19 pandemic on the current and future prospects of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market across various geographies. Further, the report provides accurate data related to the business continuity and contingency strategies adopted by leading market players operating in the Platelet Rich Plasma and Stem Cell Alopecia Treatment market.

The quantitative and qualitative assessment of the various segments of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market enables stakeholders, investors, upcoming and established market players to devise robust business development strategies. The report tracks the recent developments within the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in terms of innovation, technological progress, regulatory framework, supply chain bottlenecks, and more.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2640669&source=atm

Major Doubts Pertaining to the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Addressed in the Report

Segmentation Analysis of the Platelet Rich Plasma and Stem Cell Alopecia Treatment Market

The growth potential of the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in each region is accurately depicted in the report. The market attractiveness index included in the report enables readers to identify the most lucrative pockets within the Platelet Rich Plasma and Stem Cell Alopecia Treatment market and make informed business decisions.

The report throws light on the adoption pattern of different products along with a thorough analysis of the pricing and supply-demand ratio of each product.

Competitive Landscape

The competitive landscape section of the report tracks the business proceedings of the key players operating in the Platelet Rich Plasma and Stem Cell Alopecia Treatment market. The pricing, marketing, sales, and promotional strategies adopted by each market player is represented in the report. The contingency strategies of different players amidst the COVID-19 pandemic are touched upon in the presented report.

Market: Drivers and RestrainsThe research report has incorporated the analysis of different factors that augment the markets growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future. The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026. This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Segment Analysis The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Regional AnalysisThe research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Competitive LandscapeThis section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.Following are the segments covered by the report are:Androgenic AlopeciaCongenital AlopeciaCicatricial Or Scarring AlopeciaBy Application:HospitalDermatology ClinicOtherKey Players:The Key manufacturers that are operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market are:KerastemEclipseRegen Lab SAStemcell TechnologiesRepliCel Life SciencesHistogenGlofinn Oy.Competitive LandscapeThe analysts have provided a comprehensive analysis of the competitive landscape of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market with the company market structure and market share analysis of the top players. The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2640669&source=atm

Key Findings of the Report

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2640669&licType=S&source=atm

Link:
Coronavirus (COVID-19) Business Impact Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size of Dynamics, Products, Application Forecast...

Read More...

Betty Star Ajani Russell Watches Anime in the Bathtub as a Form of Self-Care – W Magazine

May 1st, 2020 9:44 pm

In the new HBO show Betty, the term "Betty" is used as a somewhat derogatory term by male skateboarders who see women skaters as posing hangers-on. The plot centers around a group of female friends living in New York City, chronicling their day-to-day lives, freely skating through the streets of Manhattan, hitting weed pens, and navigating the winding road of adulthood. Skateboarding is their escape, a means for enjoyment, and a form of expressiondisparaging comments about whatever veiled intentions they seem to have, be damned.

For the actress Ajani Russell, who plays Indigoa young woman trying to mask her silver-spoon upbringing from her homegirlsskincare and makeup are linked to her artistic interests. The Brooklyn-born 22-year-old lives in Los Angeles, where she's been attending classes at Cal Arts and is currently holed up at home during quarantine with her roommate, creating characters using wacky makeup and taking baths to pass the time. Like skating, modeling, and multimedia art projects, beauty is a way for Russel to flesh out her own ideas and gain inspiration. She sees makeup as something that is no longer relegated to one gender or another, a "Betty" or not. It's just a way to have fun, get creative, and for now, stave off some boredom.

Here, Russell shares her favorite K-beauty products, why skincare is the most important part of the beauty process, and why, despite a traumatic experience on a photoshoot set, she still feels invigorated by the fashion industry.

Its interesting to me that your character in Betty gets scouted to be a model, and you also were cast to model in the Rag and Bone show this past fashion week. Its like art imitating life.

The script is based loosely on things that happened to us in real life. Theyre all topics were passionate about, discussing from our perspectivesthings that havent been seen before, necessarily, on this type of platform. That was one of the things that was the important for us to share with people.

There's a scene in the show in which you're modeling in a photo shoot, and the photographer instructs you to Give me food stamps, give me WIC! That really happened to you?

It was something I experienced a few years ago. They didnt say those words exactly, but the context of the shoot, was a girl gang shoot, cool girls in groups, different types of girl gangs. I showed up to set, and it was mostly trying to be a Chola, Uptown, Latina vibe, but they were cornrowing Russian modelss hair, it was at 7 in the morning, and there was no breakfast. They put a fake scar on one girl, and a fake tattoo on another girl. I heard the makeup artist be like, Make it more ghetto. I was talking to the other models, and they were so uncomfortable. Im Puerto Rican and I was very offended. It was traumatic for me. I left that shoot, I didnt actually follow through with it because once I was in hair and makeup, I looked in the mirror and I was furious.

Despite this negative experience, I noticed on your Instagram and also in the show that beauty and fashion do seem like ways of expressing yourself.

I love beauty, and fashion and I love how both can be tied into art. I'm studying art, so I find myself being inspired by modelingit informs my art, which then informs my skateboarding, and whatever Im working on at the moment.

What are your favorite go-to beauty products?

I am big on skincare, and I love a nice glowa dewy, moisturized look. I have dry skin, so I love Korean beauty. I like Innisfree products. I have this J.One Jelly Pack Primer, which acts as a top layer for all my moisture products. Another one is the Shiseido Aqua Label Special Gel Cream. I bought it at the airport in Japan because I was flying to Milan and I needed a moisturizer. I had been flying all week and my skin was so thirsty. I asked the woman in the cosmetics shop, What is your favorite, most moisturizing product? And she pointed this one out.

Did you learn any beauty tips from your Betty costars?

How to place little gem accessories in patterns on my face, and using different colors for makeup that I would have never thought to try. I remember one episode, Dede [Lovelace] had on neon green mascaraI've used other colors like purple and red on my eyelashes, but not those hot pinks and vibrant colors. That was so cool.

What was one good beauty trick you picked up from the makeup artist Natalie Young on set?

Natalie would do skincare routines with us. After the day was done, she would wash our face with a cold makeup remover cloth, which she would dip in ice, then wipe off all our makeup with it, and then she would put a hot towel on our faces. Then she'd apply serum, and a final light moisturizer. I remember when I was shooting the movie, Skate Kitchen, the makeup artist didnt have a process like Natalie did. I remember my skin was breaking out at that time, because I have very sensitive skin and Im not used to wearing makeup all the time. But the makeup artist on Betty was really attentive to my skin needs.

Natalie was really fun and loved to play around with looks. If there was a look I was really inspired by that I found on Instagram, I'd be like, Can we do something like this? Shed be like, Lets do it. She was all for trying out colors and glitter. I actually found this brand of makeup, Kosas, through her. They have liquid glitter pigments, cream blushes, and highlighters that I love.They also have a tinted skin oil, and it makes my skin look like butter.

What products, if any, did you wear on set?

I dont usually wear makeup on the day-to-day. I like mascara and bronzer or highlighter. I use The Balm cosmetics, they have this nice bronzer called the Betty Lou-manizer.

How have you seen your beauty regimen change in quarantine?

In quarantine, Im making characters with makeup, just because I think its fun and Im bored.

I did a campaign for Wet 'n' Wild a while back. They did this Pac Man collaboration last year, and they sent me the stuff, but I had never used it because its all crazy colors. So now, I'm trying it out. They have blue lip gloss that Ive been really into lately.And I've been doing lots of face masks.

Is there any face mask in particular that youre loving right now?

Im using Formula 10.0.6 Deep Down Detox Ultra-Cleansing Mud Mask. Its a mask with orange and bergamot.

So its not a sheet mask.

No, this ones a clay mask. For paper or sheet masks, theres this Korean brand Malie System that has all these different types of masks. I got the variety pack, with aqua, pomegranate, pearl, snail, and stem cell masks, which I love.

Whats your nightly bedtime beauty routine now?

I wash my face. I have two facial cleansers: one is a Shea Moisture African Black Soap, and its a facial scrub. I use that one, or I use La Roche Posay's cleanser. But I dont think I like the La Roche Posay one as muchit dries out my skin.

But everyone swears by that brand.

Yeah, my roommate was the one who recommended it to me. But you gotta find your own routine, and listen to your skin.

When you wake up in the morning, whats the first thing you do?

I wash my face, with just water. Ill pat my face down and then Ill put on Whamisa's Organic Flower Deep Rich Essence Toner. I love this toner so much. During the day, I use APieu Pure Block Aqua Sun Gel. I put it on every day, since Im in California, and I like to go outside and be in the sun. And I also love the Dr. Barbara Sturm eye cream. That stuff, I dont know what it isits like magic. Itll give you baby eyes.

Whats your ideal spa day and where?

I dont do too many spa days, but if I had to choose, probably a Korean bathhouse. My Korean friend took me one time to a bathhouse in Los Angeles. She was like, youre going to sit in this water for 40 minutes, and when I come back, Im going to scrub you. She scrubbed down my whole body, and there were layers of skin melting off of me. It was so crazy. [Laughs.]. She got some kind of satisfaction she got from scrubbing all my skin off. She was like, Now youre baby smooth.

I also went to the Dr. Sturm store in New York once to get the Glow Facial, I believe it's called. I dont remember the womans name, but she had magic hands. She made me look like a baby: like, two years old, fresh out the womb, theres not a pore in sight on my skin.

Youve gotta find out what that womans name is.

I know. We were talking about her kids, we were really bonding. I have her card somewhere, I saved it in my wallet.

What is your favorite form of self care?

My favorite form of self care probably involves a face mask, a cup of tea, and a bathwatching anime in the bath is my favorite thing to do. I did that two days ago, because I was skateboarding, and I fell. My knee was so swollen so I took a bath. I was in there for, like, two hours and I came out all wrinkled, and my roommate was like, youve been in there for a while. I was wondering if you were okay.

Bathing is an underrated, restorative beauty act. I love soaking in natural hot springs.

I did that once in Tokyo, but only once. And I wish I could do it every single day.

Related: Betty Director Crystal Moselle on the Skate Culture Tipping Point

View post:
Betty Star Ajani Russell Watches Anime in the Bathtub as a Form of Self-Care - W Magazine

Read More...

Kelly Osbournes heartache over socially distancing from Ozzy and Sharon after coronavirus scare – 7NEWS.com.au

May 1st, 2020 9:44 pm

The daughter of rock legend Ozzy Osbourne and talk-show favourite Sharon, Kelly was always destined for a career in the spotlight.

After topping the charts, Kelly became a staple of the silver screen - but she really found her groove on TV, critiquing celebrity style and showing that unapologetic Osbourne family wit.

Watch the full story above

Now, Kelly is taking the social distancing message to her millions of followers - making headlines with her Stay Home for Ozzy campaign.

There were so many people that werent looking at this in a way which I thought was appropriate, Osbourne said.

It was very selfish, like its not going to affect me.

A lot of people dont have someone to stay home for. So I thought, if you are a fan of my dad and one of those people who dont have parents anymore, then maybe if I do this, people will stay home for my dad.

It did work and it made people look at it differently.

And Im encouraging people to think about everyone else.

Kelly is currently in isolation in Los Angeles and went three weeks without seeing her parents Ozzy and Sharon as they are both high-risk.

Sharon is a cancer survivor, and Ozzy is battling Parkinsons disease.

My dad has been doing a new stem cell treatment, which is actually working, Osbourne.

I think hes frustrated because hes feeling better so he wants to get out and do stuff, and he cant.

My dad has technically been living under quarantine rules for a year and a half. So now that hes feeling better, its so frustrating for him.

He is very, very strict about who were letting in the house, and keeping everything clean.

I am not there - I dont ever want to go into the house.

We do have to work together this week, so the company we are working with is providing us with tests and that way, I can be in the same room as him - but I refuse to be any closer than 12 feet to him.

Its just not worth the risk.

Kelly was also showing symptoms of coronavirus at one point - but has since been tested and confirmed negative.

After the negative test result, she shared an emotional video of her first hug with brother Jack since the pandemic broke.

I can honestly tell you it was the best hug I have ever had in my life, Osbourne said.

It will make me cry, I cant talk about it. Me and him, I hadnt touched another human in over two months. And to get that moment with him was so nice.

We both had a little tear I afterwards.

Like everyone else, I have fears and anxiety about it - but the way I have been looking at it is we will never have a time like this ever again, Osbourne said.

I took the time to think about what else is broken that I needed to fix - whether its things in my house, whether its that box of stuff I promised I would unpack and organise five years ago - and fixing the last little pieces which were broken in me.

More on 7NEWS.com.au

I started working out again, and Im just getting used to being happy with me in my own time.

Granted, I have those moments when I feel sorry for myself - but this was the choice I made.

It has been difficult, but it is for everyone. I just try and think about how I can help rather than sit here and complain.

Visit link:
Kelly Osbournes heartache over socially distancing from Ozzy and Sharon after coronavirus scare - 7NEWS.com.au

Read More...

CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United…

May 1st, 2020 9:44 pm

VANCOUVER, Washington, April 27, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced conditional acceptance by the U.S. Food and Drug Administration (FDA) of the proprietary name Vyrologix (pronounced - vie-ro-loj-iks) for leronlimab as a combination therapy for highly treatment experienced HIV patients in the United States. In addition, the Company has also received a notice of allowance from the U.S. Trademark Office for the Vyrologix mark.

Final approval of Vyrologix as the proprietary name for leronlimab is conditional on FDA approval of the Companys Biologics License Application and new drug application.

We are pleased to receive the FDAs conditional acceptance of Vyrologix as the proprietary name for leronlimabs combination therapy treatment of HIV, said Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn. This acceptance builds on the exceptional results from our clinical trials and our collaboration with Vyera Pharmaceuticals to commercialize and market this potential treatment to fulfill the unmet needs of HIV patients. We are also excited about the stylized Vyrologix mark and logo, which we will share immediately upon acceptance of our U.S. trademark application.

The Company also announced the appointment of Michael D. Mulholland as Interim Chief Financial Officer, who most recently served as Executive Advisor to the CEO and Senior Vice President-Finance. Mr. Mulholland joined the Company in December 2012 and served as Chief Financial Officer, Treasurer and Corporate Secretary until November 2019.

Dr. Pourhassan, stated, We are pleased to have Mike return to a senior leadership role. His deep experience and knowledge will help us navigate through the myriad of opportunities before us and assist our team to maximize shareholder value.

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH. Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting a Phase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is at http://www.cytodyn.com.

Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companys cash position, (ii) the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv) the Companys ability to enter into partnership or licensing arrangements with third parties, (v) the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companys ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companys clinical trials, (viii) the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498[emailprotected]

Excerpt from:
CytoDyn Announces Vyrologix as Proprietary Name for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients in the United...

Read More...

Jini’s Curry Feeds the Hungry with Pay Forward Lunch Program – Maui Time

May 1st, 2020 9:44 pm

Sarojini Harris and team at Jinis Curry will give 30 meals today in their Pay Forward Program

Sarojini Harris, owner and chef behind Jinis Curry is no stranger to feeding hungry folk, but she is taking it to the next level with her Pay Forward Program. Her small family restaurant has been doing take out at the Promenade Food Court since October of 2013. She is open during COVID-19, one of the food options in Wailuku town open from 11am to 2pm for pick up orders. Her menu features curry, dahl, samosas, salad and other lunch plate options. I like to order family style from Jini, so I request curry and dahl in large amounts rather than plate size, and bring home for multiple meals.

Harris says her business has dropped by 80% during this shutdown, but because of her loyal returning customers she remains operational. Harris has been offering free entrees on every plate to first responders and also feeding hungry houseless looking for food. She has had a policy of not turning away hungry and helpless if they cannot pay for years, but realized it is more important than ever during this time.

She set up the Pay Forward lunch pick up program to expand on those concepts. Her first sponsorships came from her customers and sisters Bhagyadeep Singh and Hardeep Singh. They gave their stimulus money to feed Maui residents who lost their jobs and are still waiting for unemployment benefits. You can sponsor a meal as you pick up lunch by adding a little extra to your bill if you are paying by credit card, or dropping some cash into a basket at the register. You can also email Harris at fijiindianfood@gmail.com.

To sign up to get one of her sponsored meals call or text 808-276-7215 to reserve either a chicken curry plate, or vegan curry plate. Her first 30 meals sold out and will be distributed today, May 1st. She is doing another run of meals on Wednesday May 6. Then another is planned for the following Wednesday.

Harris also has $25 and $100 gift vouchers to buy by phone if you want to call in and pay forward meals.

Jinis CurryFiji Indian Food LLCPromenade Foodcourt #4

2050 Main Street, Wailuku, HI 96793Phone: 808-243-3454

Cell: 808-276-7215Website:www.fijiindianfood.com

Facebook:www.facebook.com/FijiIndianFoodLlc

More Coronavirus Coverage from MauiTime:

comments

Read more here:
Jini's Curry Feeds the Hungry with Pay Forward Lunch Program - Maui Time

Read More...

CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -…

May 1st, 2020 9:44 pm

54 eINDs approved by FDA and 49 patients have been treated with leronlimab thus far

VANCOUVER, Washington, April 30, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY), (CytoDyn or the Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced updates on 49 COVID-19 patients who have received leronlimab under the U.S. Food and Drug Administrations (FDA) emergency Investigational New Drug (eIND) program:

Eleven (11) Patients in NY hospital: All treated patients were in Intensive Care Units (ICU) because of acute respiratory failure, eight of whom were intubated (placed on mechanical ventilation). One patient was not intubated because of poor baseline pulmonary status (history of lung cancer and had undergone bilateral upper lobectomy). Seven patients were organ-transplant recipients (six patients were renal-transplant recipients and one patient had a history of heart transplant) and were on immunosuppressive regimen. Ten patients were on dialysis and nine were on vasopressors during hospitalization. Despite their pre-existing and severe conditions, we believe we were able to save the lives of four patients. All patient blood samples were evaluated and important powerful results from the effect of leronlimab were demonstrated in almost all of these patients. This data has been submitted to a prestigious journal and we expect the publication on Friday, May 1.

Twenty-three (23) patients in Southern California hospital: Six patients were in critical condition (intubated) and 17 patients were severely-ill, needing oxygen support. No death was reported. Out of 6 critical patients, all were intubated patients, 3 were extubated (taken off ventilator), 2 patients remain relatively stable and still breathing with the assistance of a ventilator and one patient has shown deterioration in respiratory parameters. Of 17 severe condition (but not critical) patients, 11 patients demonstrated improvement in respiratory parameters (8 of them were discharged from hospital, including one patient in the news, Samantha Mottet), 2 patients remain relatively stable, 2 have shown deterioration in respiratory parameters and information is pending for 2 recently treated patients.

Three (3) patients in Georgia hospital: All three ICU patients were intubated and two of them had renal failure at the start of leronlimab treatment. Of these 3 patients, 2 were extubated (taken off ventilator) and 1 patient remains on a ventilator but improving.

One (1) patient in another NY hospital: Patient was taken off oxygen and discharged from hospital after leronlimab treatment.

One (1) patient in Northern California hospital: Patient is now weaning from ventilator and transferred to rehabilitation hospital.

Updates are pending for 10 other patients. Five additional patients have been approved to receive leronlimab under eINDs, which increases the total eINDs approved by the FDA to 54 patients.

Bruce Patterson, M.D., Chief Executive Officer and founder of IncellDx, a diagnostics company and an advisor to CytoDyn, expanded on these findings by stating, We are excited that patients are responding extremely well to leronlimab as expected from the novel mechanism of COVID-19 pathogenesis we discovered and will be reporting in the coming days.

Nader Pourhassan, Ph.D., President and Chief Executive Officer of CytoDyn said, We believe these results, although anecdotal, are very impressive and the number of patients treated under eIND is rapidly increasing. The enrollment for our Phase 2 double-blind and Phase 2b/3 trials is moving along rapidly and we believe the results from both studies will be very powerful due to the mechanism of action (MOA) of affecting the viral load and restoring the immune system. With our first major paper very close to publication, we expect to have a second paper published shortly thereafter, as our MOA is as unique as our results.

About Coronavirus Disease 2019CytoDyn is currently enrolling patients in two clinical trials for COVID-19, a Phase 2 randomized clinical trial for mild-to-moderate COVID-19 population in the U.S. and a Phase 2b/3 randomized clinical trial for severe and critically ill COVID-19 population in several hospitals throughout the country.

Story continues

SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. The origin of SARS-CoV-2 causing the COVID-19 disease is uncertain, and the virus is highly contagious. COVID-19 typically transmits person to person through respiratory droplets, commonly resulting from coughing, sneezing, and close personal contact. Coronaviruses are a large family of viruses, some causing illness in people and others that circulate among animals. For confirmed COVID-19 infections, symptoms have included fever, cough, and shortness of breath. The symptoms of COVID-19 may appear in as few as two days or as long as 14 days after exposure. Clinical manifestations in patients have ranged from non-existent to severe and fatal. At this time, there are minimal treatment options for COVID-19.

About Leronlimab (PRO 140) The FDA has granted a Fast Track designation to CytoDyn for two potential indications of leronlimab for deadly diseases. The first as a combination therapy with HAART for HIV-infected patients and the second is for metastatic triple-negative breast cancer.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.Leronlimab has completed nine clinical trials in over 800 people, including meeting its primary endpoints in a pivotal Phase 3 trial (leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients).

In the setting of HIV/AIDS, leronlimab is a viral-entry inhibitor; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab could significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use.

In the setting of cancer, research has shown that CCR5 may play a role in tumor invasion, metastases, and tumor microenvironment control. Increased CCR5 expression is an indicator of disease status in several cancers. Published studies have shown that blocking CCR5 can reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. Leronlimab reduced human breast cancer metastasis by more than 98% in a murine xenograft model. CytoDyn is, therefore, conducting aPhase 1b/2 human clinical trial in metastatic triple-negative breast cancer and was granted Fast Track designation in May 2019.

The CCR5 receptor appears to play a central role in modulating immune cell trafficking to sites of inflammation. It may be crucial in the development of acute graft-versus-host disease (GvHD) and other inflammatory conditions. Clinical studies by others further support the concept that blocking CCR5 using a chemical inhibitor can reduce the clinical impact of acute GvHD without significantly affecting the engraftment of transplanted bone marrow stem cells. CytoDyn is currently conducting a Phase 2 clinical study with leronlimab to support further the concept that the CCR5 receptor on engrafted cells is critical for the development of acute GvHD, blocking the CCR5 receptor from recognizing specific immune signaling molecules is a viable approach to mitigating acute GvHD. The FDA has granted orphan drug designation to leronlimab for the prevention of GvHD.

About CytoDynCytoDyn is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a critical role in the ability of HIV to enter and infect healthy T-cells.The CCR5 receptor also appears to be implicated in tumor metastasis and immune-mediated illnesses, such as GvHD and NASH. CytoDyn has successfully completed a Phase 3 pivotal trial with leronlimab in combination with standard antiretroviral therapies in HIV-infected treatment-experienced patients. CytoDyn completed the filing of its BLA in April 2020 to seek FDA approval for leronlimab as a combination therapy for highly treatment experienced HIV patients. CytoDyn is also conducting a Phase 3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. CytoDyn plans to initiate a registration-directed study of leronlimab monotherapy indication. If successful, it could support a label extension. Clinical results to date from multiple trials have shown that leronlimab can significantly reduce viral burden in people infected with HIV with no reported drug-related serious adverse events (SAEs). Moreover, a Phase 2b clinical trial demonstrated that leronlimab monotherapy can prevent viral escape in HIV-infected patients; some patients on leronlimab monotherapy have remained virally suppressed for more than five years. CytoDyn is also conducting a Phase 2 trial to evaluate leronlimab for the prevention of GvHD and a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. More information is atwww.cytodyn.com.

Forward-Looking StatementsThis press releasecontains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as believes, hopes, intends, estimates, expects, projects, plans, anticipates and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements specifically include statements about leronlimab, its ability to have positive health outcomes, the possible results of clinical trials, studies or other programs or ability to continue those programs, the ability to obtain regulatory approval for commercial sales, and the market for actual commercial sales. The Companys forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i)the sufficiency of the Companys cash position, (ii)the Companys ability to raise additional capital to fund its operations, (iii) the Companys ability to meet its debt obligations, if any, (iv)the Companys ability to enter into partnership or licensing arrangements with third parties, (v)the Companys ability to identify patients to enroll in its clinical trials in a timely fashion, (vi)the Companys ability to achieve approval of a marketable product, (vii)the design, implementation and conduct of the Companys clinical trials, (viii)the results of the Companys clinical trials, including the possibility of unfavorable clinical trial results, (ix)the market for, and marketability of, any product that is approved, (x)the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companys products, (xi)regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii)general economic and business conditions, (xiii)changes in foreign, political, and social conditions, and (xiv)various other matters, many of which are beyond the Companys control. The Company urges investors to consider specifically the various risk factors identified in its most recent Form10-K, and any risk factors or cautionary statements included in any subsequent Form10-Q or Form8-K, filed with the Securities and Exchange Commission. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

CYTODYN CONTACTSInvestors: Dave Gentry, CEORedChip CompaniesOffice: 1.800.RED.CHIP (733.2447)Cell: 407.491.4498dave@redchip.com

Read the original:
CytoDyn Reports Strong Results from eIND COVID-19 Patients Treated with Leronlimab; Majority of Patients Have Demonstrated Remarkable Recoveries -...

Read More...

Kiadis Pharma announces annual results for the year ended December 31, 2019 – Yahoo Finance

May 1st, 2020 9:44 pm

Company to hold conference call for analysts and investors today at 18:00 CET

Amsterdam, The Netherlands, April 30, 2020 Kiadis Pharma N.V.( Kiadis, Kiadis Pharma or the Company) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its audited 2019 Annual Results for the year ended December 31, 2019, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

Arthur Lahr, CEO of Kiadis commented, 2019 was a transformational year for Kiadis with the acquisition of CytoSen Therapeutics in the first half; the termination of the ATIR101 development program in the second half; and the restructuring and refocus of our organization solely on Kiadis natural killer (K-NK) cell therapies in the fourth quarter. We were faced with some difficult decisions during the year, but we were always guided by our core values of always doing what is right and putting our patients first. In the face of adversity, I am proud of the decisions that our team has made and believe that we have emerged in 2020 as a stronger organization.

Key Developments (including post reporting period)

Revenue & Other IncomeThe Group did not record revenue and/or other income in 2019 and 2018.

Operating Expenses

OPERATING RESULTSAs a result of the overall increase in total operating expenses, the Group's operating loss increased from EUR25.2 million in 2018 to EUR73.2 million in 2019.

NET FINANCIAL RESULT

NET RESULTAs a result of the above items, the loss for the year increased by EUR22.8 million to EUR52.6 million in 2019 versus a loss of EUR29.8 million in 2018. CASH FLOWSTotal cash and cash equivalents decreased by EUR30.8 million from EUR60.3 million at year-end 2018 to EUR29.5 million at the end of 2019. This decrease mainly results from the net operating cash outflow amounting to EUR48.3 million, capital expenses of EUR4.5 million and repayments of outstanding loans of EUR5.7 million, offset by the net proceeds of a share offering for a total amount of EUR25.3 million and cash balances of CytoSen for an amount of EUR3.1 million, which we acquired on June 5, 2019.

EQUITYThe Company's equity position amounted to EUR34.3 million at year-end 2019 versus EUR44.1 million at the end of 2018, a decrease of EUR9.8 million. The main drivers of this decrease are the loss for the year of EUR52.6 million offset by net proceeds of a share offering of EUR25.3 million in total and shares issued upon the acquisition of a business combination.Earnings per shareThe undiluted loss per share for 2019 increased to EUR 1.92 compared to EUR 1.46 in 2018.

Annual Report

The Annual Report 2019 is available on Kiadis Pharmas website.

Conference Call and PresentationTo participate in the conference call, please call one of the following numbers ten minutes prior to commencement of the call:Standard International: +44 (0) 2071 928338Netherlands, Amsterdam: +31 (0) 207956614UK, London: +44 (0) 8444819752US, New York: +16467413167US, toll free: 18778709135

Event Plus Passcode: 4968027

A live audio webcast of the call can be accessed from the Events and Presentations section of the Companys website, https://ir.kiadis.com/events-and-presentations or at https://edge.media-server.com/mmc/p/6ctgdx37.

For more information, please contact:

About Kiadis Pharmas K-NK-Cell Therapies

Kiadis Pharmas K-NK platform is designed to deliver potent NK cells to help each patient, without the need for genetic engineering. Kiadis Pharmas programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.

The Companys PM21 particle technology enables improved ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Kiadis Pharmas proprietary off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Story continues

Kiadis Pharma is developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT, and K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. In addition, Kiadis Pharma has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.

About Kiadis PharmaFounded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life. The Companys shares are listed on the Euronext Amsterdam and Brussels under the ticker KDS. Learn more at http://www.kiadis.com.Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com.

Forward Looking StatementsCertain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharmas or, as appropriate, Kiadis Pharmas officers current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such persons officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

See original here:
Kiadis Pharma announces annual results for the year ended December 31, 2019 - Yahoo Finance

Read More...

Study: Exercise More Effective Than Weight Loss for Improving Heart Function in Diabetes – Drug Topics

May 1st, 2020 9:43 pm

A study completed by the University Hospitals at Leicester showed that heart function in patients with type 2 diabetes (T2D) may be improved more effectively through exercise training than through a weight loss regimen.

The study was funded by the National Institute for Health Research (NIHR) and similarly conducted at the NIHR Leicester Biomedical Research Centre (BRC).

Heart failure is one of the most common complications in people with type 2 diabetes, and younger adults with type 2 diabetes already have changes in their heart structure and function that pose a risk of developing heart failure, Gaurav Gulsin, a BHF clinical research fellow at the University of Leicester, trainee heart physician, and a lead author of the study, said We wanted to confirm the abnormalities in the structure and function of the heart in this patient population using the latest scanning techniques, and explore whether it is possible to reverse these through exercise and/or weight loss.

The randomized study incorporated a total of 87 participants, between 18 and 65 years of age, with type 2 diabetes, who underwent echocardiography and a magnetic resonance imaging (MRI) scan in order to verify their early heart dysfunction, as well as exercise tests to analyze cardiovascular fitness. Patients were randomly selected into 1 of 3 groups routine care, supervised aerobic exercise training, or low-energy meal replacement program all of which lasted for 12 weeks; 76 participants remained on the program for the entire duration of the study.

Researchers from the University Hospitals of Leicester reported that those who followed the supervised exercise program demonstrated significantly improved heart function compared with the control group.

The results also suggested that while a low-energy diet did not alter heart function, the program did show favorable effects on heart structure, vascular function, and diabetes reversal in 83% of the patient group.

Limitations of the study included small population size and failure of nearly 1 in 5 patients in the exercise arm of the study to complete the program, effectively restricting the studys application in future clinical practice.

Senior study author Gerry McCann, NIHR research professor and professor of cardiac imaging at the University of Leicester and a consultant cardiologist at Leicesters Hospitals said, Through this research we have shown that lifestyle interventions in the form of regular exercise training may be important in limiting and even reversing the damage to heart structure and function seen in younger adults with type 2 diabetes. While losing weight has a beneficial effect on heart structure, our study shows that on its own it does not appear to improve heart function.

The findings have been published in the journal Diabetes Care.

Read this article:
Study: Exercise More Effective Than Weight Loss for Improving Heart Function in Diabetes - Drug Topics

Read More...

How Close Are We To Creating A Fully Automated Diabetes Kit? – AI Daily

May 1st, 2020 9:43 pm

An estimated 425 million people globally have diabetes, accounting for 12% of the world's health expenditure. Living with diabetes is no easy feat, for people with type one diabetes missing a meal or going for an unplanned walk could dangerously reduce their blood glucose level, and severe low blood sugar at night may mean that regaining consciousness is impossible - a daunting thought for people to have to face when they live alone

In recent years technological developments have progressed and an enhanced algorithm has been created which is available in the US and expected in Europe within months, and it allows the pump to act as an automated delivery system as it guides insulin dosing in response to changes in blood glucose levels. This development is hugely beneficial as type one diabetics can now wear two small interconnected electronic devices that have significantly reduced the risk of falling blood sugar levels at night. A continuous glucose monitor (CGM) can check their blood sugar levels in real-time and communicate with a programmable insulin pump that delivers tiny amounts of insulin into the tissue under their skin. The technology has continued to improve its ease of use; users now spend less time inputting details of what they are to eat and they are less vulnerable to the effects of stress, hormones, and alcohol on their blood sugar level. Yet the system isnt perfect - many users still report frequently waking up in the middle of the night from the CGM warning them of high blood sugar levels or that the pump needs to be topped up with insulin.

These kinds of systems help to regulate sugar levels, avoid highs and lows and make the users' lifestyle significantly easier by reducing the need for constant monitoring and top-ups of insulin. Technologies like this are provided by devices from companies such as Medtronic and Diabeloop, and by CamDiabs CamAPS FX an Android phone app designed to work with commercially available insulin pumps and CGMs.

As with all medical technological developments, each new generation of devices has to go through a lengthy process of regulatory approval, which has consequently driven some people with diabetes to build their own DIY systems, using algorithms to control insulin dosing based on data from their CGMs. These DIY systems are able to automate the majority of the calculations that each individual would normally do whilst measuring their blood sugar levels, to make predictions and adjust insulin dosing, not only does the use of an automated system reduce the adjustments that people have to make themselves and the mental strain that comes with living with diabetes but also minimizes the chances of wrong predictions or insulin dosing due to human error.

Despite the growth of automated systems for diabetes, widespread adoption of these systems seems to have plateaued, one reason being the expenses rising up to 3,000-4,500 a year taking acquisition, maintenance and the need to replace pumps every few years into account. Recently, more research has been done into creating a more cost-effective method for creating an automated diabetes kit. An example of this is the smartpen, which are handheld devices for injecting insulin record details about the time and quantity of a patients dose and transmitting them to a mobile phone app via Bluetooth, used in combination with a CGM, the app can them advise people with diabetes on the amount of insulin they should take, costing under 1000 a year.

But pumps, CGMs and pens involve repeated skin piercing. The answer to these issues seems to lie with the use of electrocardiogram signals to track glucose levels and by applying artificial intelligence algorithms to a heartbeat scan, machines using ECG are able to detect low glucose with accuracy to match a CGM monitor, whilst being non-invasive and environmentally friendly due to the minimal waste produced. Trials with diabetic patients are to begin soon and wearable ECG-based monitors could be on the market within a few years with huge potential to still grow and develop in order to ease human experience, possibly by being incorporated into smart fabrics, so there is no need to wear separate devices.

Predictive algorithms, artificial intelligence and machine learning are beginning to tackle the issues that diabetics face in their day to day lives, and the future prospects for a completely automated system are promising, potentially providing a risk-free future for people living with the disease.

Read more:
How Close Are We To Creating A Fully Automated Diabetes Kit? - AI Daily

Read More...

R. Kelly Says He’s Likely Diabetic and Takes Third Shot at Jail Release – TMZ

May 1st, 2020 9:43 pm

Breaking News

R. Kelly has no shame ... he's making yet another plea to the judge to let him out of jail, but this time he claims he has proof he's vulnerable to COVID-19.

The disgraced singer's lawyer filed docs, obtained by TMZ, asking the judge to release his client pending his trial and claiming the Bureau of Prisons failed to disclose Kelly's medical tests from March showing he is "likely diabetic."

In docs, Kelly's lawyer also claims the singer has high cholesterol and high blood pressure ... further putting him in a vulnerable position if he contracts the deadly coronavirus while penned up at MCC Chicago.

The judge has not yet made a decision on whether to release Kelly. TMZ broke the story ... he swung and missed TWICE last month. During Kelly's first attempt, the judge denied him saying, among other things, the singer is a flight risk. Not long after, his team made a second attempt, but again, the judge said no dice.

The judge had previously expressed concern Kelly might intimidate witnesses if he's allowed out of jail. Kelly addresses that in the new docs, referring to one of his former girlfriends who used to visit him regularly in jail and correspond with him. He says during all those visits he was well aware she is one the Jane Doe victims in his case, and still never attempted to obstruct justice.

He doesn't name her, but our Kelly sources tell us he's talking about Azriel Clary, who's now working with the prosecution. Kelly says if he had tried to intimidate her, she would have reported him to prosecutors by now.

Normally, they say the third time's a charm, but R. Kelly's a different story ... for so many reasons.

Read more here:
R. Kelly Says He's Likely Diabetic and Takes Third Shot at Jail Release - TMZ

Read More...

Can a new tool for diabetes patients solve the problem of COVID-19 testing? – News@Northeastern

May 1st, 2020 9:43 pm

When Ming L. Wang developed a new way to test glucose levels in saliva to monitor diabetes, he wasnt thinking of making COVID-19 tests.

But after he saw the lack of testing options in the U.S. as COVID-19 cases skyrocketed, Wang decided to turn his testing device into something people could use to track the spread of SARS-CoV-2, the coronavirus that causes the illness.

The current tests sometimes take too long, says Wang, distinguished professor of civil and environmental engineering at Northeastern. You need to take a few days, and sometimes do the tests many times to minimize false negatives.

Ming Wang is a distinguished professor of civil and environmental engineering at Northeastern. Photo courtesy Ming Wang

For nearly a decade, Wang has been perfecting his glucose testing device, which can perform quick and easy tests from saliva samples. That test kit uses a disposable chip equipped with sensors to detect glucose moleculesno finger pricks, doctors, or pain involved. It was patented in 2018 and is now being tested in preclinical trials, Wang says.

Now, Wang is reconfiguring the devices biosensor to test for SARS-Cov2 molecules in the saliva of people who carry the coronavirus and give an accurate diagnosis within three minutes of testing.

Wang says that device is intended to work even in the early stages of infection, before the onset of COVID-19 symptoms. And it is designed to detect antibodies in an effort to help determine whether someone who has recovered from the disease might be protected from it in the future.

Thats very important, Wang says. You need to know who has had it to test someones immunity after contracting the virus.

Testing during the early stages of infection is critical, Wang says, because reports have shown that people can shed the coronavirus before showing some of the most common symptoms of COVID-19, even without ever displaying them.

Wangs tests are intended to be accurate enough to be used in healthcare facilities, but also practical enough to be used at home and without the need for healthcare personnel.

As scientists around the world speed up their research to learn more about the unknowns behind the coronavirusabout immunity and transmission, for exampleWang says rapid home tests can help people answer one of the most important questions of the COVID-19 pandemic: How do I know if Ive got the virus?

Recent estimates in the U.S. suggest that the coronavirus has been spreading far more widely and efficiently than health officials thought, suggesting it moves silently amongst people who havent yet developed symptoms. Those estimates underscore the importance of having a quick and accurate tool that people can use at home, Wang says.

The biosensor within the device is designed to use gold nanoparticles to read tiny signals produced as the coronavirus interacts with key protein molecules to hijack human cells and replicate into millions more of itself. The sensor then reads the signals released by those interactions to detect the coronavirus.

Wang says he is focusing on sampling saliva because the method produces fast results without being invasive.

The most common tests for COVID-19 first insert a cotton swab into a persons throat, lungs, or nose to sample the genetic material of the coronavirus, and then rely on a technique called polymerase chain reaction, which involves making millions of copies of the genetic material to determine the presence of the coronavirus. The entire process can take several hours or days to complete.

And while new methods have been recently developed to help healthcare personnel test for the coronavirus using saliva, the key is in using a simple electronic device that relies on the chemistry within saliva to test in minutes and without specialized biotechnicians, Wang says.

You could use it for port entry facilities, you could use it for physician offices, urgent care centers, nursing facilities, he says. It takes about two-three minutes to complete, and about $10 per test.

Wangs coronavirus testing kits will take at least 6 months to develop. Still, he is hopeful they will come out during a time when there is an urgent need for new technology that can serve as the basis for future tests to help prevent other global health emergencies such as COVID-19or recurring ones.

We could be expecting the second or third run of COVID-19 to come next winter in 2021, maybe up to 2022 or beyond, Wang says. Once this platform is set and we can use it, we can redesign the sensor for other viral infections.

For media inquiries, please contact Jessica Hair at j.hair@northeastern.edu or 617-373-5718.

Read more:
Can a new tool for diabetes patients solve the problem of COVID-19 testing? - News@Northeastern

Read More...

3 "Non-Coronavirus Stocks" That Would Have Doubled Your Money Over the Last Year – Motley Fool

May 1st, 2020 9:43 pm

"Coronavirus stocks," the stocks of companies that make products and provide services that are experiencing strong demand stemming from the COVID-19 pandemic, have been getting a ton of attention. (Indeed, like many financial writers, I recently wrote an article on the topic, outlining8 top coronavirus stocks.)

However, some stocks that don't fall into this category have also been strong performers in recent months, as well as over the long term. For instance, you'd have more than doubled your money had you invested in these "non-coronavirus stocks" a year ago: diabetes specialists Insulet and DexCom and real estate investment trust Safehold.

Image source: Getty Images.

Company

Market Cap

Forward P/E

Projected Annualized5-Year EPS Growth*

YTD 2020 Return (Loss)

1-Year Return

10-Year Return

S&P 500

Data sources: Yahoo! Finance and YCharts. Data as of April 30, 2020. P/E = price-to-earnings ratio. EPS = earnings per share. YTD = year to date. *Wall Street's consensus estimate.

If you're looking for a growth market in which to invest, I'd suggest the diabetes space. Unfortunately, the incidence of the disease (both type 1 and type 2) has been rising around the world. Indeed, many healthcare experts consider diabetes an epidemic in the United States and many other countries.

Two top names in the diabetes space are medical-device makers Insulet and DexCom. Insulet makes the leading tubeless insulin pump, the Omnipod, and DexCom produces acontinuous glucose monitoring (CGM) system, the G6.

In fact, these two companies are partners. In the second half of this year,Insulet plans to launch its Horizon automated insulin delivery system, which uses aDexCom CGM. Moreover, the Horizon system's insulin pump will be controlled by a smartphone.

On Tuesday, DexCom reported its first-quarter 2020 results, which crushed Wall Street's expectations. Sales rose 44% year over year to $405.1 million, sailing by the$357.6 million analyst consensus estimate. Adjusted earnings per share (EPS) landed at $0.44, compared to the year-ago period's loss of $0.05 per share. This result demolished the consensus estimate of $0.14.

Insulet is scheduled to report first-quarter results on Thursday, May 7, after market close.

Image source: Getty Images.

Safehold is a real estate investment trust (REIT) that specializes in commercial property (but no retail) ground leases in the 25 largest markets in the U.S.It buysthe land underlying commercial real estate projects, which it leases back to the owners of the structures on the land. The company uses the rental income to grow the business and pay shareholders a modest dividend, currently yielding 1.2%.

Safehold was founded in 2016 andheld itsinitial public offeringin 2017, so it's relatively small for a REIT and doesn't have much of a track record.That said, it seems worth watching.

Like most companies, Safehold expects to have some near-term pain due to the pandemic. By the end of the first quarter, deals were largely on hold across the commercial real estate market. However, management also believes the company should bounce back quickly once the dust settles a bit. Here's what CEO Jay Sugarman had to say during the April 23 first-quarter earnings call:

We continue to be engaged in conversations with customers on a number of fronts, and would expect our better price, more efficientcapital to be in demand once there's more clarity about the future. We expect deals put on hold may very well come back, and thatexisting customers will find the opportunities to deploy capital and seek our help in capitalizing those opportunities. ...

As for the existing portfolio, all of our ground leases paid [their rent] in April.

In the first quarter, Safehold's revenue soared 84% year over year to $40.2 million. Net income jumped 56% to $17.4 million, which translated to earnings per share coming in flat with the year-ago period at $0.36. (The number of shares outstanding increased, which is why EPS was only flat while net income rose significantly.)

Go here to read the rest:
3 "Non-Coronavirus Stocks" That Would Have Doubled Your Money Over the Last Year - Motley Fool

Read More...

Type 2 Diabetes Treatment Market Growth Opportunities, Challenges, Key Companies, Drivers and Forecast to 2026 Cole Reports – Cole of Duty

May 1st, 2020 9:43 pm

F. Hoffmann-La Roche Ltd

Global Type 2 Diabetes Treatment Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Type 2 Diabetes Treatment Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Type 2 Diabetes Treatment market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Type 2 Diabetes Treatment market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=31462&utm_source=COD&utm_medium=001

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Type 2 Diabetes Treatment world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Type 2 Diabetes Treatment market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Type 2 Diabetes Treatment world industry from 2020 to 2026 is provided to determine the potential of the Type 2 Diabetes Treatment market.

This Type 2 Diabetes Treatment Market Report Answers To Your Following Questions:

Who are the main global players in this Type 2 Diabetes Treatment market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Type-2-Diabetes-Treatment-Market/?utm_source=COD&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Type 2 Diabetes Treatment Market Size, Type 2 Diabetes Treatment Market Trends, Type 2 Diabetes Treatment Market Growth, Type 2 Diabetes Treatment Market Forecast, Type 2 Diabetes Treatment Market Analysis

See the original post:
Type 2 Diabetes Treatment Market Growth Opportunities, Challenges, Key Companies, Drivers and Forecast to 2026 Cole Reports - Cole of Duty

Read More...

Taysha Gene Therapies hits the ground running with $30M, 15 programs – FierceBiotech

May 1st, 2020 9:42 pm

The team that developed Zolgensma is back for round two. A group of former AveXis executives and investors unveiled a new gene therapy company, and theyre wasting no time. With 15 programs, $30 million in seed funding and an unrivaled partnership with UT Southwestern Medical Center, Taysha Gene Therapies plans to be in the clinic by the end of the year.

Its working on adeno-associated vector (AAV) gene therapies for monogenic diseasesthat is, diseases caused by a defect in a single geneof the central nervous system. Tayshas lead program targets GM2 gangliosidosis, a very rare disorder that progressively destroys nerve cells in the brain and spinal cord, but the companys portfolio includes conditions that are more prevalent.

The company plans to start clinical trials for three more programs by the end of 2021: treatments for Rett syndrome, a neurodevelopmental disorder; SURF1 deficiency, the most frequent cause of Leigh syndrome; and a SLC6A1 genetic epilepsy, which is similar to Dravet syndrome, Taysha CEO and co-founder R. A. Session II told FierceBiotech.

FiercePharma Presents the Virtual eRegulatory Operations Summit

Join industry experts and learn how to build and manage cohesive, compliant, and timely electronic submissions through innovative technologies and seamless clinical documentation processes.

RELATED: Passage Bio pulls off $216M IPO, blowing past original goal

And thats not allTaysha has the option to pick up four more prospects from UT Southwestern.

The reason why we can tackle 15 programs with the option to four additional programs is were able to focus on what we do best and were able to allow our collaborators to focus on what they do best, Session said.

Under their partnership, UT Southwestern is working on discovery and preclinical work all the way through IND-enabling studies. It has its own GMP viral manufacturing site to support that work, as well as clinical development, which Taysha will pick up. The company will also take care of regulatory strategy, commercial manufacturing and commercialization. Its a skill set that Tayshas management team honed at AveXis as itdeveloped the gene therapy that eventually became Novartis spinal muscular atrophy treatment Zolgensma.

We essentially flew the plane and built it at the same time when we were developing AveXis We have people with the experience of being able to develop, manufacture and commercialize a gene therapy program and were marrying that with a best-in-class academic research institution, Session said.

RELATED: FDA lets Novartis off the hook in Zolgensma data manipulation

Dividing the labor creates this engine for innovation that allows the partners to advance many programs in parallel, Session added. With about 50 people in its gene therapy unit, UT Southwestern can develop a capsidthe protein shell of a virusfor treatment delivery or get a candidate into animal models much more quickly than a biotech going it alone, he said. The same goes for late-stage development and commercialization on Tayshas side.

For its initial programs, Taysha is focusing on AAV gene therapies because the team knows they work.

AAV9 is the best way we have to treat monogenic CNS disease. If its not broke, dont fix it, Session said. We know how to effectively dose AAV9; we know its safe, effective and efficient. And we know its scalable. These are problems we had to solve at our previous company.

But, moving forward, Taysha and UT Southwestern are working on new technologies, including an AAV delivery platform that would allow for the redosing of gene therapies as well as an AAV capsid platform aimed at improving target delivery.

The rest is here:
Taysha Gene Therapies hits the ground running with $30M, 15 programs - FierceBiotech

Read More...

Dallas Gene Therapy Startup Launches with $30M Seed Round and a UT Southwestern Partnership – dallasinnovates.com

May 1st, 2020 9:42 pm

R.A. Session II, president, CEO, and founder of Taysha Gene Therapies [Background image: Olena Yepifanova via iStock]

Dallas-based biotech Taysha Gene Therapies has emerged out of stealth with a $30 million seed round and a new strategic partnership with UT Southwestern. The company aims to end severe and life-threatening diseases of the central nervous system caused by variation in a single gene, also known as monogenic CNS diseases.

Hitting the ground running, the company launches with a pipeline of 15 adeno-associated virus gene therapy programs, along with options to four others.

Taysha plans human testing this year and expects to file four Initial New Drug applications in 2021. In addition, the biotech is developing an improved treatment delivery platform that uses machine learning, DNA shuffling, and something it calls directed evolution.

The gene therapy startup closed its round of seed financing in early March just as the Dow dropped a couple of thousand points, according to a report in EndpointsNews.

If you had to ask me, was I worried? Absolutely. I think I wouldnt be human if I wasnt, RA Session II, president, CEO, and founder of Taysha, told the healthcare publication.

Session had a lot of certainty to balance out all the uncertainty of launching a new biotech during a pandemic, noted Endpoints Amber Tong.

The experience of a proven management team, including some who previously led the development and commercialization of the first FDA-approved gene therapy for CNS disease, Zolgensma, is part of the equation.

The startup intends to combine the speed, scale, and expertise of its partners UT Southwestern Gene Therapy Program with the experience of the Taysha team.

Session says the launch reunites former investors and executives from AveXis. Tayshas funding round was co-led by PBM Capital, the first institutional investor in AveXis, and Nolan Capital, the investment fund of former AveXis CEO Sean Nolan.

Tayshas Board of Directors played a key role in the formation of the company, it said. The board is comprised of Sean Nolan, Paul Manning of PBM Capital, Claire Aldridge, Ph.D., of UT Southwestern, and RA Session II, President, CEO, and Founder of Taysha.

Nolan, who serves as Chairman of the Board, sees promise in Tayshas approach for patients suffering from many devastating CNS diseases.

This is an exciting time for gene therapy, he said.

The strategic partnership with UT Southwestern could help Taysha to rapidly and efficiently translate novel AAV gene therapies from bench to bedside, the company said.

UTSW is home to some of the brightest minds in gene therapy, Sessions says. By joining forces with UT Southwestern, Taysha can advance its potential cures with both speed and scale.

The collaboration is ultimately creating an engine for new cures, said Claire Aldridge, Ph.D., a Taysha board member and associate vice president of commercialization and business development at UT Southwestern Medical Center.

Together, Taysha and UTSW will merge cutting-edge translational research, hands-on clinical care, and expertiseboth regulatory and commercial, she said.

Aldridge has already witnessed how quickly and efficiently the partners can leverage their collective expertise and resources. That means getting new gene therapies to the patients who so desperately need them, she said.

The UT Southwestern Gene Therapy Program, led by Steven Gray, Ph.D., Director of the Viral Vector Core and Assistant Professor in the Department of Pediatrics, and Berge Minassian, M.D., Division Chief of Child Neurology, has the capacity to support Tayshas wide range of preclinical and clinical development programs, the company said.

Under the partnership, UT Southwestern, which has developed a state-of-the-art viral vector manufacturing facility, will run discovery and preclinical research, as well as lead studies, provide manufacturing, and execute natural history studies.

For its part, Taysha will lead all clinical development, regulatory strategy, commercial manufacturing, and commercialization activities, according to the company.

A joint steering committee of key leadership members from Taysha and UT Southwestern will govern the collaboration.

Sign up to keep your eye on whats new and next in Dallas-Fort Worth, every day.

The free, five-day celebration of all things startup is officially underway.

Browse our curated selection of events to plan your next week and beyond.

Friday morning's Startup Week activities led off with a women's networking breakfast and a Creative Mornings event. Then, sessions have covered equity in real estate, corporate innovation, fundraising, and the future of philanthropy.

Thursday led off with a session delving into blockchain's use in health care and events giving tips in SEO, influencer marketing, and legal issues.RevTech also hosted its signature Tech Trends in Retail event.

Wednesday's panels have tackled disruptive technologies such as blockchain, the corporate-startup relationship, and more.

Read the original here:
Dallas Gene Therapy Startup Launches with $30M Seed Round and a UT Southwestern Partnership - dallasinnovates.com

Read More...

Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies – Yahoo Finance

May 1st, 2020 9:42 pm

Biotech executive, Julia Berretta, Ph.D., is named Chief Executive Officer

Genespire, a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, announced today the successful close of a 16M Series A financing from Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan. The company also announced the appointment of Julia Berretta, Ph.D., as Chief Executive Officer and member of the Board of Directors. Graziano Seghezzi, Managing Partner at Sofinnova Partners, and Lucia Faccio, Ph.D., Partner at Sofinnova Partners, will also join the Board.

Genespire was founded in March 2020 as a spin-off of the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget), one of the worlds leading cell and gene therapy research institutes spearheaded by gene therapy pioneer Prof. Luigi Naldini. The Company was co-founded by Fondazione Telethon and the San Raffaele Hospital, along with Prof. Naldini and Dr. Alessio Cantore.

The funds will be used to advance Genespires leading-edge platform technologies towards the development of novel gene therapies in two main areas: primary immunodeficiencies and metabolic genetic diseases.

"Our mission has always been to develop breakthrough solutions for genetic diseases," said Prof. Naldini, Genespires co-founder and Director of SR-Tiget. "This financing enables the company to translate our innovative science and early stage programs into clinical development. The appointment of Dr. Berretta as CEO is a major reinforcement of our team."

Sofinnova Partners Dr. Faccio added, "Genespire is an exciting investment with all the key ingredients for success: Outstanding scientists that developed the first ex-vivo gene therapy to market, experienced executives brought in through Sofinnova Partners network and game changing technologies that have the potential to impact the lives of patients with genetic diseases."

"I am thrilled to be joining Genespire and such exceptional scientific founders," said Dr. Berretta. "Genespire was born of decades of experience in the gene therapy field, and is optimally positioned to advance transformative therapies for patients affected by severe inherited diseases."

Dr. Berretta was part of the Executive Committee of Cellectis S.A., a Nasdaq-listed clinical stage gene editing company developing CAR-T cell therapies for cancer, where she led business development as well as strategic planning. She is also an independent Board member of Treefrog Therapeutics, an innovative stem cell company.

About Genespire

Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases. Based in Milan, Italy, Genespire was founded in March 2020 by the gene therapy pioneer Prof. Luigi Naldini, Dr. Alessio Cantore, Fondazione Telethon and Ospedale San Raffaele. It is a spin-off of SR-Tiget, a world leading cell and gene therapy research institute and is backed by Sofinnova Partners. http://www.genespire.com

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, with offices in London and Milan, the firm brings together a team of 40 professionals from all over Europe, the U.S. and Asia. The firm focuses on paradigm-shifting technologies alongside visionary entrepreneurs. Sofinnova Partners invests across the Life Sciences value chain as a lead or cornerstone investor, from very early-stage opportunities to late-stage/public companies. It has backed nearly 500 companies over more than 48 years, creating market leaders around the globe. Today, Sofinnova Partners has over 2 billion under management.

For more information, please visit: http://www.sofinnovapartners.com

About Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit: http://www.telethon.it

Story continues

About Ospedale San Raffaele

Ospedale San Raffaele (OSR) is a clinical-research-university hospital established in 1971 to provide international-level specialised care for the most complex and difficult health conditions. OSR is part of Gruppo San Donato, the leading hospital group in Italy. The hospital is a multi-specialty center with over 60 clinical specialties; it is accredited by the Italian National Health System to provide care to both public and private, national and international patients. Research at OSR focuses on integrating basic, translational and clinical activities to provide the most advanced care to our patients. The institute is recognized as a global authority in molecular medicine and gene therapy, and is at the forefront of research in many other fields. Ospedale San Raffaele is a first-class institute which treats many diseases and stands out for the deep interaction between clinical and scientific area. This makes the transfer of scientific results from the laboratories to the patients bed easier. Its mission is to improve knowledge of diseases, identify new therapies and encourage young scientists and doctor to grow professionally. For more information, please visit: http://www.hsr.it

About the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200429005417/en/

Contacts

Julia BerrettaCEO, Genespire S.r.linfo@genespire.com +39 02 83991300

Bommy LeeHead of Communications, Sofinnova Partnersblee@sofinnovapartners.com +33 (0) 6 47 71 38 11

North AmericaRooneyPartners LLCKate Barrettekbarrette@rooneyco.com +1 212 223 0561

FranceStrategiesImage (S&I)Anne Reinanne.rein@strategiesimage.com +33 6 03 35 92 05

Originally posted here:
Genespire Secures 16 Million Series A Financing from Sofinnova Partners to Advance Transformative Gene Therapies - Yahoo Finance

Read More...

Page 572«..1020..571572573574..580590..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick